Stay updated with breaking news from V Wave Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
For an all-comer population with any impairment of LV function, an interarterial shunt device missed the primary endpoint in RELIEVE-HF, but benefit was seen with LVEF less than 40%.
/PRNewswire/ -- V-Wave today announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology's (ACC)...
/PRNewswire/ -- V-Wave, announced today the completion of enrollment in RELIEVE-HF, a prospective, randomized, double-blinded, sham-controlled, multi-center...
/PRNewswire/ -- V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with...
/PRNewswire/ -- V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with...